GammaDelta Therapeutics Ltd has expanded its leadership team with the appointment of Paolo Paoletti as chief executive officer and Natalie Mount as chief scientific officer. The company was founded in 2016 to develop immunotherapies for cancer by exploiting tissue resident gamma delta T cells. Dr Paoletti is joining the company from Kesios Therapeutics Ltd where he was CEO. He was previously the first president of GSK Oncology.
Dr Mount is joining from the Cell and Gene Therapy Catapult where she was chief clinical officer.
GammaDelta has also named Dayle Hogg as chief operating officer, while Raj Mehta, the company’s interim CEO and commercial founder, will become director of intellectual property, alliance management and business development.
GammaDelta Therapeutics announced the appointments on 3 May 2017
Copyright 2017 Evernow Publishing Ltd